Madrigal Pharmaceuticals, Inc. (MDGL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
MDGL Revenue Growth
Revenue Breakdown (FY 2025)
MDGL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
MDGL Revenue Analysis (2014–2025)
As of May 8, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) generated trailing twelve-month (TTM) revenue of $1.13 billion, reflecting explosive growth of +126.8% year-over-year. The most recent quarter (Q1 2026) recorded $311.3 million in revenue, down 3.0% sequentially.
Looking at the longer-term picture, MDGL's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $958.4 million in 2025, representing a new all-time high.
Revenue diversification analysis shows MDGL's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including HIMS (+59.0% YoY), MDGL has outperformed the peer group in terms of revenue growth. Compare MDGL vs HIMS →
MDGL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| MDGLCurrent | $1.1B | +126.8% | - | -31.3% | |
 HIMS | $2.3B | +59.0% | +73.6% | 5.2% |
MDGL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $958.4M | +432.1% | $902.3M | 94.1% | $-300,097,000 | -31.3% |
| 2024 | $180.1M | - | $173.9M | 96.5% | $-497,875,000 | -276.4% |
| 2023 | $0 | - | $0 | - | $-380,496,000 | - |
| 2022 | $0 | - | $0 | - | $-293,571,000 | - |
| 2021 | $0 | - | $0 | - | $-242,482,000 | - |
| 2020 | $0 | - | $-471,000 | - | $-206,320,000 | - |
| 2019 | $0 | - | $-112,000 | - | $-94,972,000 | - |
| 2018 | $0 | - | $-96,000 | - | $-40,456,000 | - |
| 2017 | $0 | - | $-77,000 | - | $-31,886,000 | - |
| 2016 | $0 | - | $-156 | - | $-24,981,641 | - |
Full MDGL Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See MDGL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MDGL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MDGL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMDGL — Frequently Asked Questions
Quick answers to the most common questions about buying MDGL stock.
Is MDGL's revenue growth accelerating or slowing?
MDGL revenue is accelerating at +126.8% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $1.1B. Growth momentum has increased versus prior periods.
What is MDGL's long-term revenue growth rate?
Madrigal Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +126.8% is above this long-term average.
How is MDGL's revenue distributed by segment?
MDGL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.